UNSPSC 51361939: Probarbital sodium

This classification denotes a barbiturate with the molecular formula C9H13N2O3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YDA0W423G6, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-5-(1-methylethyl)-, monosodium salt (9ci) but more generally known as probarbital sodium, which bears US NIH Compound Identifier 67414. European Medicines Agency schedules Probarbital sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10052MIG.

UNSPSC 51361939 Probarbital sodium is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent state and local opportunities tagged under this code reflect a much broader procurement landscape centered on naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals rather than probarbital sodium specifically. State and local issuing bodies soliciting under this code include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances. Seminole County, Florida, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the recent buyers active in this space. The work itself spans naloxone procurement for community health initiatives, direct-to-manufacturer pharmacy benefit programs, and generic pharmaceutical supply agreements with authorized wholesalers.

Activity is concentrated in Florida and Minnesota, with Texas conducting early-stage market intelligence through a Request for Information. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 (note: this date appears inconsistent with the posting date and may reflect a data entry error in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program, signaling early exploration rather than an imminent formal RFP. Most substantially, MMCAP posted RFP S1070000015802 on January 20, 2026, with responses due March 26, 2026, to establish multi-year contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities, including Oregon, with contract terms effective July 1, 2026. Vendors must work through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson) and comply with cGMP and DSCSA requirements.